Physician profile
Robert C Jamieson
NPI 1184602757
$141,446.83
in general payments reported to CMS, 2019-2025
57 companies · $1,370 in 2025
The $1,370 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $27K · 2021: $26K · 2022: $33K · 2023: $9,240 · 2024: $1,572 · 2025: $1,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,600 · Food and Beverage: $5,512 · Travel and Lodging: $57.64 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,600.00 |
| Food and Beverage | $5,512.29 |
| Travel and Lodging | $57.64 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $30,556.06 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30,099.54 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $28,447.34 | 2019-2025 | Ingrezza |
| Abbvie INC. | $21,966.76 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11,539.36 | 2019-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $9,189.73 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $3,054.28 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $818.04 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $641.56 | 2019-2024 | Spravato, Invega Sustenna |
| Alkermes, INC. | $569.03 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $481.71 | 2019-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $304.15 | 2019-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Vanda Pharmaceuticals INC. | $296.71 | 2019-2022 | |
| Axsome Therapeutics, INC. | $284.08 | 2022-2024 | Auvelity, Sunosi |
| Amgen INC. | $277.70 | 2019-2024 | Repatha, Otezla |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jamieson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.